Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Food Effect of HS-10398 in Healthy and Renal Impaired Participants
NCT06383897Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HS-10398 in IgA nephropathy (IgAN) and membranous nephropathy (MN) (5 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Incidence and severity of adverse events and Serious adverse events. Planned start May 2024; status: not yet recruiting.
02
Drugs
HS-10398
03
Conditions
IgA nephropathy (IgAN)membranous nephropathy (MN)
Beyond the preview
Go deeper on NCT06383897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383897.